

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Healthia Limited
<b>ABN</b>	85 626 087 223

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Colin Jonathan Kangisser
<b>Date of last notice</b>	20 September 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<ol style="list-style-type: none"><li>Indirect</li><li>Direct</li></ol>
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"><li>Bridell Pty Ltd as trustee of the Kangisser Family Trust ACN 062 133 493. Colin Jonathan Kangisser is a director and shareholder of the trustee and a beneficiary of the trust.</li><li>Colin Jonathan Kangisser</li></ol>
<b>Date of change</b>	<ol style="list-style-type: none"><li>Not applicable</li><li>29 November 2022</li></ol>
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"><li>5,134,628</li><li>45,000</li></ol>
<b>Class</b>	<ol style="list-style-type: none"><li>Ordinary Class Shares</li><li>Performance Rights – each being a conditional entitlement to one ordinary share in the Company in accordance with the Company's Performance Rights Plan.</li></ol>
<b>Number acquired</b>	<ol style="list-style-type: none"><li>Nil</li><li>(a) 245,625 FY23 Performance Rights (b) 115,643 Retention Performance Rights</li></ol>
<b>Number disposed</b>	<ol style="list-style-type: none"><li>Nil</li><li>Nil</li></ol>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"><li>Not applicable</li><li>Performance rights form part of Directors' remuneration and are issued for nil consideration.</li></ol>

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>5,134,628</li> <li>406,268</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> <li>Not applicable.</li> <li> <ol style="list-style-type: none"> <li>Security holder approval was obtained at Healthia's Annual General Meeting on 29 November 2022 (<b>the AGM</b>) to issue 2023 Performance Rights to Directors pursuant to the Company's Performance Rights Plan (<b>the Plan</b>), which was approved by shareholders at the AGM.</li> <li>Security holder approval was obtained at the AGM to issue Retention Performance Rights to Directors pursuant to the Plan, which was approved by shareholders at the AGM.</li> </ol> </li> </ol>

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A